Pinealon dosing schedule
> Updated:
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
Pinealon (Glu-Asp-Arg, EDR) is administered mainly subcutaneously, once daily, in research protocols. The schedule below is a reference generalized from described regimens and the reconstituted product, not a clinically validated protocol.
This is a concise reference to regimens described for adults; it is not an individual prescription.
Pinealon searches usually target a specific day-by-day schedule for the whole course rather than a single injection, so the dose is listed below by day exactly as described in the sources, with no clinical status attached.
| Period / condition | Dose | Escalation |
|---|---|---|
| Days 1–5 | 1.0 mg (1000 mcg) once daily, subcutaneous | Starting dose |
| Days 6–14 | 1.5 mg (1500 mcg) once daily, subcutaneous | Increase if needed |
| Days 15–20 | 2.0 mg (2000 mcg) once daily, subcutaneous | Maximum in this schedule |
Practical dosing and course details
In this schedule the Pinealon dose does not increase daily; it moves in three steps by course day: 1.0 mg on days 1–5, 1.5 mg on days 6–14, 2.0 mg on days 15–20. That is a typical structure for a short peptide course: hold the lowest dose for several days, then step up, rather than changing the dose every day.
The course length here is fixed at 20 days rather than open-ended, so the total peptide given over the course is set by the length of each step, not only by the peak dose on days 15–20.
Added up, the first step (5 days at 1.0 mg) totals 5 mg, the second (9 days at 1.5 mg) totals 13.5 mg, and the third (6 days at 2.0 mg) totals 12 mg. The middle step contributes the most to the overall total: its longer duration outweighs the higher daily dose of the final step.
Daily subcutaneous administration, rather than every other day or less often, reflects the usual logic for short-lived peptides in these protocols: a steady daily rhythm sustains the administered level across the whole course window.
This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.